SCHEMBL487415

SCHEMBL487415

Brc1nc2ccccc2c2[nH]cnc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PRNP P04156 2/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
PDPK1 O15530 1/20 0.41
CA12 O43570 1/20 0.41
PARP1 P09874 1/20 0.41
ALOX15 P16050 1/20 0.41
CA9 Q16790 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
DYRK1A Q13627 2/20 0.40
CSNK2A2 P19784 1/20 0.40
RAB9A P51151 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507881 0.83 SMN1; SMN2 (0.41) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL212131 0.79 TLR7 (0.44) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL9076301 0.79 SMN1; SMN2 (0.41) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL29694218 0.79 TLR7 (0.44) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL5528653 0.79 GPR3 (0.48) ALDH1A1HPGDSMN1; SMN2PDPK1CA12
SCHEMBL487627 0.79 MAOA (0.42) ALDH1A1HPGDSMN1; SMN2PDPK1CA12
SCHEMBL311169 0.79 JAK2 (0.41) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL7072625 0.79 SMN1; SMN2 (0.41) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL5523405 0.78 RAB9A (0.44) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1486424 0.78 SMN1; SMN2 (0.40) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106202-B2 Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor FERRER INTERNACIONAL, S.A. (ES) 2012-01-31 US disclosed
EP-1879893-B1 METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR FERRER INT (ES) 2010-06-02 EP disclosed
US-20090005566-A1 Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor FERRER INTERNACIONAL, S.A. (ES) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005566-A1 Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor CYP4B1, QARS1, CYP4F11 ALDH1A1 271/4885HPGD 1513/4885SMN1; SMN2 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.